Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 3/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | NOS1 | P29475 | 2/20 | 0.47 |
| ▸ | NOS2 | P35228 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5117533 | 0.91 | LMNA (0.53) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| SCHEMBL7611304 | 0.84 | CYP4A11 (0.58) | LMNACYP1A2CYP3A4CA1CA2 | |
| SCHEMBL8302756 | 0.84 | LMNA (0.59) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| SCHEMBL12199135 | 0.83 | CA1 (0.68) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| SCHEMBL5734417 | 0.80 | LMNA (0.68) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| SCHEMBL9844686 | 0.80 | CYP1A2 (0.54) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| SCHEMBL571227 | 0.80 | CA1 (0.63) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL9261439 | 0.79 | LMNA (0.66) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| SCHEMBL7482018 | 0.79 | CA12 (0.58) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 | |
| SCHEMBL1244233 | 0.78 | CA1 (0.61) | LMNACYP1A2CYP3A4MAOASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10543282-B2 | Targeted peptide conjugates | MARKER GENE TECHNOLOGIES, INC (US) | 2020-01-28 | — | — | US | disclosed |
| US-20180207287-A1 | TARGETED PEPTIDE CONJUGATES | MARKER GENE TECHNOLOGIES, INC. | 2018-07-26 | — | — | US | disclosed |
| US-9925271-B2 | Targeted pharmacological chaperones | MARKER GENE TECHNOLOGIES, INC (US) | 2018-03-27 | — | — | US | disclosed |
| US-20170216451-A1 | TARGETED PHARMACOLOGICAL CHAPERONES | MARKER GENE TECHNOLOGIES, INC. | 2017-08-03 | — | — | US | disclosed |
| US-9610358-B2 | Targeted pharmacological chaperones | MARKER GENE TECHNOLOGIES, INC (US) | 2017-04-04 | — | — | US | disclosed |
| US-20160228422-A1 | TARGETED PHARMACOLOGICAL CHAPERONES | MARKER GENE TECHNOLOGIES, INC. | 2016-08-11 | — | — | US | disclosed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-03 | — | — | US | disclosed |
| EP-1828124-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | Galderma Research & Development (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006063863-A1 | BIAROMATIC COMPOUNDS THAT MODULATE PPAR TYPE RECEPTORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN COSMETIC OR PHARMACEUTICAL COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160228422-A1 | TARGETED PHARMACOLOGICAL CHAPERONES | HSPA5, HSPE1, HSP90B1 | LMNA 1260/4885CYP1A2 3606/4885CYP3A4 4182/4885 |
| US-20170216451-A1 | TARGETED PHARMACOLOGICAL CHAPERONES | HSPA5, HSPE1, HSP90B1 | LMNA 1215/4885CYP1A2 3737/4885CYP3A4 4270/4885 |
| US-20180207287-A1 | TARGETED PEPTIDE CONJUGATES | VCP, NLN, GOLT1B | LMNA 1345/4885CYP1A2 4226/4885CYP3A4 4240/4885 |
| US-20080004274-A1 | Novel biaromatic compounds that modulate PPAR type receptors and cosmetic/pharmaceutical compositions comprised thereof | PPARG, PPARD, PPARA | LMNA 3355/4885CYP1A2 262/4885CYP3A4 878/4885 |
| US-10543282-B2 | Targeted peptide conjugates | VCP, NLN, GOLT1B | LMNA 1345/4885CYP1A2 4226/4885CYP3A4 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.